Photo of David Zhang

David Zhang

  • PROFESSOR Pathology
  • PROFESSOR Oncological Sciences
  • ASSOCIATE PROFESSOR Preventive Medicine
Print ProfilePrint Profile

Specialty

Certifications

  • Occupational Medicine

  • Molecular Genetic Pathology

  • Cytopathology

  • Anatomic & Clinical Pathology

Education

  • MD, Norman Bethune Univ of Medical Sciences

  • Ph.D., NYU School of Medicine

  • MPH, Mount Sinai School of Medicine

  • Residency, Pathology
    Mount Sinai Hospital

  • Residency, Occupational Medicine
    Mount Sinai Hospital

  • Fellowship, Clinical Microbio
    Mount Sinai Hospital

  • Fellowship, Cytopathology
    Mount Sinai Hospital

Research

Certifications:
Anatomic and Clinical Pathology, Cytopathology, Molecular Genetic Pathology, Preventive Medicine (Occupational Medicine)

Specific Clinical/Research Interest:
Clinical Interest: Providing molecular diagnostic tests in the areas of cancer prognosis and therapy, pharmacogenetics, hematologic disorders,and infectious diseases.

Research Interest: Molecular cancer biology with focus on cancer biomarker discovery and technology development including genomics and proteomics for cancer diagnosis and prognosis.

Current Students: Xiufen Liu, Wei Li, Wuhan Hui

Postdoctoral Fellows: Weihua Tong MD, PhD

Research Personnel: Fei Ye PhD, Clinical Assistant Professor; Josephine Wu DDS, JD, Assistant professor

Summary of Research Studies:
We developed a signal transduction pathway-focused proteomic method, termed PROTEIN PATHWAY ARRAY (PPA), which can be used to globally screen the signaling proteins and their activation. With the assistance of computation, we are able to identify key node, hubs, pathways and signaling network that controls cell proliferation, apoptosis, angiogenesis, necrosis, etc. This method has been used to identify novel candidate proteins as cancer biomarkers for diagnosis and prognosis and/or as targets for cancer treatment. We also invented several DNA amplification technologies, including the rolling circle amplification (RCA), isothermal ramification amplification assay (RAM) and hybridization signal amplification (HSAM). These technologies have been granted by the US Patent Office and licensed to Hamilton Thorne Biosciences, a biotechnology company based in Boston. RAM, unlike conventional polymerase chain reaction (PCR), can amplify DNA, RNA and protein without the use of thermocycling. It is extremely sensitive and can detect as few as 10 molecules. HSAM is another signal amplification technology based on the principles of nucleic acid hybridization and specific ligand interaction. This technology is simple and sensitive to identify DNA/RNA targets and proteins and can be apply to in situ amplification, DNA arrays, and proteomics.

Publications

Cheng L, Zhang DY, editors. Essentials of Molecular Genetic Pathology (2007). New York, Humana/Springer Press;.

Wang H, Huang M, Zhang DY, Zhang F. Global profiling of signaling networks: study of breast cancer stem cells and potential regulation. The oncologist 2011; 16(7).

Wang H, Gillis A, Zhao C, Lee E, Wu J, Zhang F, Ye F, Zhang DY. Crocidolite asbestos-induced signal pathway dysregulation in mesothelial cells. Mutation research 2011 Aug; 723(2).

Wang D, Ye F, Sun Y, Li W, Liu H, Jiang J, Zhang Y, Liu C, Tong W, Gao L, Sun Y, Zhang W, Seetoe T, Lee P, Suo J, Zhang DY. Protein signatures for classification and prognosis of gastric cancer a signaling pathway-based approach. The American journal of pathology 2011 Oct; 179(4).

Zhang DY, Ye F, Gao L, Liu X, Zhao X, Che Y, Wang H, Wang L, Wu J, Song D, Liu W, Xu H, Jiang B, Zhang W, Wang J, Lee P. Proteomics, pathway array and signaling network-based medicine in cancer. Cell division 2009; 4.

Yi J, Zhang W, Zhang DY. Molecular Zipper: a fluorescent probe for real-time isothermal DNA amplification. Nucleic acids research 2006; 34(11).

Zhang D, Wu J, Ye F, Feng T, Lee I, Yin B. Amplification of circularizable probes for the detection of target nucleic acids and proteins. Clinica chimica acta; international journal of clinical chemistry 2006 Jan; 363(1-2).

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Zhang did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Insurance Information

Mount Sinai Health System (MSHS) physicians - including those employed by MSHS - do not always participate in the same health plans in which MSHS hospitals or facilities participate.

Information regarding insurance participation and billing by this physician may be found on this page or obtained by contacting this provider directly.

Insurance plans that the Mount Sinai Health System hospitals or facilities participate in can be found on the Mount Sinai Health System website.

Edit profile in Sinai Central

Address

Icahn Medical Institute Floor 9th Room 9-82 (Lab)
1425 Madison Avenue
New York, NY 10029

Tel: 212-659-8164

Address

Icahn Medical Institute Floor 9th Room 9-52
1425 Madison Avenue
New York, NY 10029

Tel: 212-659-8173